FIELD: biotechnology.
SUBSTANCE: group of inventions relates to stable aqueous solutions containing an antibody to C5 in a high concentration and methods for the production of these solutions. The stable aqueous solution contains an antibody to C5 at a concentration of 100 mg/ml ± 5%, 50 mM ± 5% of a phosphate buffer, 5% ± 5% of sucrose. In another option, the solution also contains 0.05% ± 5% of polysorbate 80. The antibody to C5 contains a heavy chain with SEQ ID NO: 14 and a light chain with SEQ ID NO: 11. Methods for the treatment or prevention of disorders associated with C5 complement system, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome (aHUS), using these solutions, are also proposed. Therapeutic kits containing the specified solution and a means for administration of the solution to a patient who needs treatment are also presented.
EFFECT: invention provides a stable highly concentrated aqueous solution of an antibody to C5, which remains for at least 97% monomeric and preserves at least 90% of its C5-binding activity during storage at 2-8°C for at least six months.
27 cl, 53 dwg, 23 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
DOSES AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) | 2020 |
|
RU2822664C2 |
DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING ANTI-C5 CROVALIMAB ANTIBODY | 2020 |
|
RU2832188C2 |
ANTIBODIES AGAINST E-SELECTIN, COMPOSITIONS AND METHODS OF USE | 2021 |
|
RU2805176C1 |
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
COMPOSITION CONTAINING ANTIBODY AGAINST ABETA PROTOFIBRILS AND INHIBITOR OF BETA-SECRETASE BACE1 FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2786476C2 |
STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2020 |
|
RU2829637C2 |
ANTI-COMPLEMENT COMPONENT 5 ANTIBODY MOLECULES AND USE THEREOF | 2019 |
|
RU2830091C2 |
Authors
Dates
2023-01-11—Published
2018-07-27—Filed